EZH2 and acute myeloid leukemia: Regarding EZH2 itself, the nature of its role in cancer and AML in particular appears complex and remains to be fully resolved (Yamaguchi and Hung, 2014; Safaei et al., 2018; Wang and Wang, 2020; Huang et al., 2021), with uncertain implications for this enzyme as a therapeutic target in AML (Eich et al., 2020; Zeng et al., 2022).